How many stocks are there of Altimmune?
The current number of stocks of Altimmune is 53.25 M undefined.
Altimmune Stocks 2025
Altimmune Stocks
53.25 M
Ticker
ALT
ISIN
US02155H2004
WKN
A2N5Z6
In 2025, Altimmune had 53.25 M outstanding stocks, a 0% change from the 53.25 M stocks in the previous year.
The Altimmune Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2030e | 53.25 |
| 2029e | 53.25 |
| 2028e | 53.25 |
| 2027e | 53.25 |
| 2026e | 53.25 |
| 2025e | 53.25 |
| 2024e | 53.25 |
| 2023 | 53.25 |
| 2022 | 46.93 |
| 2021 | 41.28 |
| 2020 | 25.64 |
| 2019 | 13.12 |
| 2018 | 2.8 |
| 2017 | 0.43 |
| 2016 | 0.23 |
| 2015 | 0.21 |
| 2014 | 0.19 |
| 2013 | 0.17 |
| 2012 | 0.16 |
| 2011 | 0.16 |
| 2010 | 0.11 |
| 2009 | 0.09 |
| 2008 | 0.08 |
| 2007 | 0.03 |
| 2006 | - |
| 2005 | - |
Altimmune shares outstanding US02155H2004 · A2N5Z6
The number of shares was Altimmune in 2024 — This indicates how many shares 53.247 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Altimmune earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Altimmune's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Altimmune’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Altimmune's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2005 | 0 Aktien |
| 2006 | 0 Aktien |
| 2007 | 30,000 Aktien |
| 2008 | 80,000 Aktien |
| 2009 | 90,000 Aktien |
| 2010 | 110,000 Aktien |
| 2011 | 160,000 Aktien |
| 2012 | 160,000 Aktien |
| 2013 | 170,000 Aktien |
| 2014 | 190,000 Aktien |
| 2015 | 210,000 Aktien |
| 2016 | 230,000 Aktien |
| 2017 | 430,000 Aktien |
| 2018 | 2.8 M Aktien |
| 2019 | 13.12 M Aktien |
| 2020 | 25.64 M Aktien |
| 2021 | 41.28 M Aktien |
| 2022 | 46.93 M Aktien |
| 2023 | 53.25 M Aktien |
| 2024e | 53.25 M Aktien |
| 2025e | 53.25 M Aktien |
| 2026e | 53.25 M Aktien |
| 2027e | 53.25 M Aktien |
| 2028e | 53.25 M Aktien |
| 2029e | 53.25 M Aktien |
| 2030e | 53.25 M Aktien |
Altimmune Aktienanalyse
What does Altimmune do?
Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA. Altimmune ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Altimmune's Shares Outstanding
Altimmune's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Altimmune’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Altimmune’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Altimmune’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Altimmune stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Altimmune are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Altimmune evolved in recent years?
The number of shares of Altimmune has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Altimmune as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Altimmune?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Altimmune pay?
Over the past 12 months, Altimmune paid a dividend of 873 USD . This corresponds to a dividend yield of about 12,278.48 %. For the coming 12 months, Altimmune is expected to pay a dividend of 0 USD.
What is the dividend yield of Altimmune?
The current dividend yield of Altimmune is 12,278.48 %.
When does Altimmune pay dividends?
Altimmune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Altimmune?
Altimmune paid dividends every year for the past 0 years.
What is the dividend of Altimmune?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Altimmune located?
Altimmune is assigned to the 'Health' sector.
Wann musste ich die Aktien von Altimmune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Altimmune from 2/3/2017 amounting to 2.91 USD, you needed to have the stock in your portfolio before the ex-date on 2/6/2017.
When did Altimmune pay the last dividend?
The last dividend was paid out on 2/3/2017.
What was the dividend of Altimmune in the year 2024?
In the year 2024, Altimmune distributed 0 USD as dividends.
In which currency does Altimmune pay out the dividend?
The dividends of Altimmune are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Altimmune
Our stock analysis for Altimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Altimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
